Firefly Neuroscience Congratulates Scientific Advisor, Dr. Christopher Wilson, Recipient of Prestigious UW Faculty of Engineering Award for Work on Superconducting Quantum Electronics
Firefly Neuroscience (NASDAQ: AIFF) announces that Dr. Christopher Wilson, a member of their Advisory Development Board, has received the Faculty Research Excellence Award from the University of Waterloo's Faculty of Engineering. Dr. Wilson, who works at the Institute for Quantum Computing (IQC), specializes in superconducting quantum electronics research.
Dr. Wilson has secured $13 million in research funding throughout his career from various international agencies. His achievements include supervising over 40 researchers, publishing more than 100 refereed publications, and co-authoring a new textbook titled 'Building Quantum Computers' published by Cambridge University Press in 2024.
The company mentions that Dr. Wilson is currently involved in a new brain model initiative at Firefly, with more details to be announced in the future.
Firefly Neuroscience (NASDAQ: AIFF) annuncia che il Dr. Christopher Wilson, membro del loro Advisory Development Board, ha ricevuto il Faculty Research Excellence Award dalla Facoltà di Ingegneria dell'Università di Waterloo. Il Dr. Wilson, che lavora presso l'Istituto per il Calcolo Quantistico (IQC), si specializza nella ricerca sull'elettronica quantistica superconduttiva.
Il Dr. Wilson ha ottenuto 13 milioni di dollari in finanziamenti per la ricerca nel corso della sua carriera da varie agenzie internazionali. I suoi successi includono la supervisione di oltre 40 ricercatori, la pubblicazione di più di 100 articoli scientifici sottoposti a revisione e la coautoria di un nuovo libro di testo intitolato 'Building Quantum Computers', pubblicato da Cambridge University Press nel 2024.
La società menziona che il Dr. Wilson è attualmente coinvolto in una nuova iniziativa di modello cerebrale presso Firefly, con ulteriori dettagli da annunciare in futuro.
Firefly Neuroscience (NASDAQ: AIFF) anuncia que el Dr. Christopher Wilson, miembro de su Junta Asesora de Desarrollo, ha recibido el Faculty Research Excellence Award de la Facultad de Ingeniería de la Universidad de Waterloo. El Dr. Wilson, que trabaja en el Instituto de Computación Cuántica (IQC), se especializa en la investigación sobre electrónica cuántica superconductora.
El Dr. Wilson ha conseguido 13 millones de dólares en financiamiento para investigación a lo largo de su carrera de diversas agencias internacionales. Sus logros incluyen supervisar a más de 40 investigadores, publicar más de 100 publicaciones revisadas por pares y ser coautor de un nuevo libro titulado 'Building Quantum Computers', publicado por Cambridge University Press en 2024.
La empresa menciona que el Dr. Wilson está actualmente involucrado en una nueva iniciativa de modelo cerebral en Firefly, con más detalles que se anunciarán en el futuro.
파이어플라이 뉴로사이언스 (NASDAQ: AIFF)는 자문 개발 위원회의 일원인 크리스토퍼 윌슨박사가 워털루 대학교 공과대학의 교수 연구 우수상(Faculty Research Excellence Award)을 수상했다고 발표했습니다. 윌슨 박사는 양자 컴퓨팅 연구소(IQC)에서 근무하며 초전도 양자 전자공학 연구를 전문으로 합니다.
윌슨 박사는 그의 경력 동안 다양한 국제 기관으로부터 1300만 달러의 연구 자금을 확보했습니다. 그의 업적에는 40명 이상의 연구원 감독, 100편 이상의 심사된 논문 발행, 그리고 2024 년에 케임브리지 대학 출판사에서 발행된 'Building Quantum Computers'라는 새로운 교과서의 공동 저자가 포함됩니다.
회사는 윌슨 박사가 현재 Firefly에서 새로운 뇌 모델 이니셔티브에 참여하고 있으며, 더 많은 세부정보는 향후 발표될 것이라고 언급했습니다.
Firefly Neuroscience (NASDAQ: AIFF) annonce que le Dr. Christopher Wilson, membre de son Conseil consultatif de développement, a reçu le Faculty Research Excellence Award de la Faculté de Génie de l'Université de Waterloo. Le Dr. Wilson, qui travaille à l'Institut de calcul quantique (IQC), se spécialise dans la recherche en électronique quantique supraconductrice.
Le Dr. Wilson a obtenu 13 millions de dollars de financement pour la recherche au cours de sa carrière de diverses agences internationales. Parmi ses réalisations, on compte la supervision de plus de 40 chercheurs, la publication de plus de 100 publications évaluées par les pairs et la coécriture d'un nouveau manuel intitulé 'Building Quantum Computers', publié par Cambridge University Press en 2024.
L'entreprise mentionne que le Dr. Wilson est actuellement impliqué dans une nouvelle initiative de modèle cérébral chez Firefly, avec plus de détails à annoncer dans le futur.
Firefly Neuroscience (NASDAQ: AIFF) gibt bekannt, dass Dr. Christopher Wilson, ein Mitglied ihres Beratenden Entwicklungsausschusses, von der Fakultät für Ingenieurwissenschaften der Universität Waterloo mit dem Faculty Research Excellence Award ausgezeichnet wurde. Dr. Wilson, der am Institut für Quantencomputing (IQC) tätig ist, spezialisiert sich auf die Forschung im Bereich der supraleitenden Quanten-Elektronik.
Dr. Wilson hat im Laufe seiner Karriere insgesamt 13 Millionen US-Dollar an Forschungsförderung von verschiedenen internationalen Institutionen gesichert. Zu seinen Errungenschaften zählen die Betreuung von über 40 Forschern, die Veröffentlichung von mehr als 100 begutachteten Publikationen und die Co-Autorenschaft eines neuen Lehrbuchs mit dem Titel 'Building Quantum Computers', das 2024 von Cambridge University Press veröffentlicht wird.
Das Unternehmen erwähnt, dass Dr. Wilson derzeit an einer neuen Gehirnmodell-Initiative bei Firefly beteiligt ist, über die in Zukunft weitere Details bekannt gegeben werden.
- None.
- None.
- University of Waterloo’s Faculty of Engineering Recognizes Dr. Wilson with Faculty Research Excellence Award -
- Esteemed researchers and engineers like Dr. Wilson are currently helping Firefly lay the groundwork for an exciting new brain model initiative to be revealed soon -
KENMORE, N.Y., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to congratulate Christopher Wilson, PhD, on being recognized by the University of Waterloo’s (“UW”) Faculty of Engineering for his significant contributions to research and scholarship. The award recognizes Dr. Wilson’s research at the Institute for Quantum Computing (“IQC”) at UW.
Dr. Wilson’s work explores the use of superconducting quantum electronics for both applications and basic science. His research brings together start-ups, academia and defense sectors in Canada and internationally, and he has secured
Dr. Wilson has supervised more than 40 research associates, postdoctoral fellows, PhD students, master’s and undergraduate students, whom he involves in international collaborations. Among his more than 100 refereed publications, 30 high-impact publications have students or postdocs as first authors. His new textbook, Building Quantum Computers, was published by Cambridge University Press in 2024. It was co-authored by IQC past Executive Director, Raymond Laflamme, and IQC PhD Student, Shayan Majady, and is based on their courses on quantum information processing taught at IQC.
Greg Lipschitz, Executive Chairman of Firefly, said, “On behalf of everyone here, I would like to extend my sincere congratulations to Dr. Wilson on this amazing achievement. In addition to his outstanding contributions to the advancement of quantum science and technology, Dr. Wilson is a vital member of Firefly’s Advisory Development Board. Most recently, he has been collaborating on an exciting new brain model initiative. We are looking forward to providing more information on that in the near future.”
About Firefly
Firefly (NASDAQ: AIFF) is an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Firefly’s FDA-510(k) cleared Brain Network Analytics (BNA™) technology revolutionizes diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has built a comprehensive database of brain wave tests, securing patent protection, and achieving FDA clearance. The Company is now launching BNA™ commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use.
Brain Network Analytics was developed using artificial intelligence and machine learning on Firefly’s extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (EEGs) of over 17,000 patients representing twelve disorders, as well as clinically normal patients. BNA™, in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function. These insights can enhance a clinician’s ability to accurately diagnose mental and cognitive disorders and to evaluate what therapy and/or drug is best suited to optimize a patient’s outcome.
Please visit https://fireflyneuro.com/ for more information.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” for purposes of the federal securities laws concerning Firefly. These forward-looking statements include express or implied statements relating to Firefly’s management teams’ expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to development and commercialization of BNA™ technology; risks related to Firefly’s ability to recognize the anticipated benefits of the merger (the “Merger”) with WaveDancer, Inc. (“WaveDancer”); risks related to Firefly’s ability to correctly estimate its operating expenses and unanticipated spending and costs that could reduce Firefly’s cash resources; the ability of Firefly to protect its intellectual property rights; competitive responses to the Merger; unexpected costs, charges or expenses resulting from the Merger; potential adverse reactions or changes to business relationships resulting from the completion of the Merger; legislative, regulatory, political and economic developments; and those factors described under the heading “Risk Factors” in the registration statement on Form S-4 filed by WaveDancer with the Securities and Exchange Commission on January 22, 2024, as amended, and declared effective on February 6, 2024. Should one or more of these risks or uncertainties materialize, or should any of Firefly’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Investor & Media Contact
Stephen Kilmer
(646) 274-3580
stephen.kilmer@fireflyneuro.com
FAQ
What award did Dr. Christopher Wilson receive from the University of Waterloo while serving as Firefly Neuroscience (AIFF) advisor?
How much research funding has Dr. Wilson secured for his quantum electronics work as AIFF advisor?
What is the new book published by Firefly Neuroscience (AIFF) advisor Dr. Wilson in 2024?
What new initiative is Dr. Wilson working on with Firefly Neuroscience (AIFF)?
